Clinical Edge Journal Scan

Postoperative accelerated partial breast irradiation noninferior to whole breast irradiation in early BC


 

Key clinical point: Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy after breast-conserving surgery is as effective as and safer than whole breast irradiation (WBI) and can be an excellent alternative to WBI in patients with early breast cancer (BC).

Major finding: The 10-year local recurrence rate was similar in the WBI (1.58%) and APBI (3.51%) groups ( P = .074), and the incidence of treatment-related late side-effects worse than grade 2 was significantly lower in the APBI vs WBI group ( P = .021).

Study details : Findings are from the phase 3, GEC-ESTRO trial including 1328 women with early invasive BC who were randomly assigned to receive WBI or APBI.

Disclosures: This study was funded by German Cancer Aid, Germany. Some authors declared receiving grants, consulting fees, financial support, or payment from several sources.

Source: Strnad V, Polgár C, et al, on behalf of Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology . Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023 (Feb 1). Doi: 10.1016S1470-2045(23)00018-9

Recommended Reading

Use of diagnostic mammograms is inconsistent, survey finds
MDedge Hematology and Oncology
Radiotherapy for early breast cancer: Sharp cutoff at age 70
MDedge Hematology and Oncology
‘Valid option’ for partial breast irradiation in breast cancer
MDedge Hematology and Oncology
Genomic clues to poor outcomes in young breast cancer patients
MDedge Hematology and Oncology
Breast cancer exacts high financial toll worldwide
MDedge Hematology and Oncology
Omit radiation in older women with low-risk, ER+ breast cancer
MDedge Hematology and Oncology
Progress in breast cancer screening over the past 50 years: A remarkable story, but still work to do
MDedge Hematology and Oncology
‘Financial toxicity’ from breast cancer is a worldwide phenomenon
MDedge Hematology and Oncology
New cancer screen, same issues: Physicians confront Galleri test
MDedge Hematology and Oncology
Real-world survival benefit with CDK4/6 inhibitors in MBC
MDedge Hematology and Oncology